

Supplementary Materials for  
Consolidated Financial Results for  
the 1st Quarter of Fiscal Year 2016. 12 (IFRS)

Innovation all for the patients



CHUGAI PHARMACEUTICAL CO., LTD.

A member of the Roche group

- Notes: 1. Portions of this report that refer to performance forecasts or any other future events are believed to be reasonable under information available at the time of the forecasts. Actual results may materially differ from these forecasts due to potential risks and uncertainties.
2. Amounts shown in this report are rounded to the nearest 0.1 billion yen. Variance and % are calculated based on the amounts
3. Exchange rates used for each period are as follows.

### QTR

(Yen)

| Average | Actual<br>FY2015 |        |        |        | Actual<br>FY2016 |     |     |       |
|---------|------------------|--------|--------|--------|------------------|-----|-----|-------|
|         | 1-3              | 4-6    | 7-9    | 10-12  | 1-3              | 4-6 | 7-9 | 10-12 |
|         | QTR              | QTR    | QTR    | QTR    | QTR              | QTR | QTR | QTR   |
| CHF     | 124.98           | 128.80 | 126.71 | 122.62 | 116.14           |     |     |       |
| EUR     | 134.38           | 134.16 | 135.94 | 132.99 | 127.29           |     |     |       |
| USD     | 119.15           | 121.32 | 122.20 | 121.47 | 115.43           |     |     |       |
| SGD     | 87.88            | 90.33  | 87.89  | 86.29  | 82.22            |     |     |       |

### YTD

| Average | Actual<br>FY2014 | Actual<br>FY2015 |        |        |           | Actual<br>FY2016 |     |     |           | Forecast<br>FY2016 |
|---------|------------------|------------------|--------|--------|-----------|------------------|-----|-----|-----------|--------------------|
|         | 1-12             | 1-3              | 1-6    | 1-9    | 1-12      | 1-3              | 1-6 | 1-9 | 1-12      | 1-12               |
|         | Full-year        | YTD              | YTD    | YTD    | Full-year | YTD              | YTD | YTD | Full-year | Full-year          |
| CHF     | 115.69           | 124.98           | 126.88 | 126.82 | 125.74    | 116.14           |     |     |           | 127.00             |
| EUR     | 140.49           | 134.38           | 134.27 | 134.83 | 134.36    | 127.29           |     |     |           | 134.00             |
| USD     | 105.84           | 119.15           | 120.24 | 120.89 | 121.03    | 115.43           |     |     |           | 120.00             |
| SGD     | 83.54            | 87.88            | 89.10  | 88.69  | 88.07     | 82.22            |     |     |           | 87.00              |

### Period-end

| As of | Actual<br>FY2014 | Actual<br>FY2015 |         |         |         | Actual<br>FY2016 |         |         |         |
|-------|------------------|------------------|---------|---------|---------|------------------|---------|---------|---------|
|       | 31 Dec.          | 31 Mar.          | 30 Jun. | 30 Sep. | 31 Dec. | 31 Mar.          | 30 Jun. | 30 Sep. | 31 Dec. |
| CHF   | 120.81           | 124.13           | 132.49  | 123.25  | 121.89  | 116.50           |         |         |         |
| EUR   | 145.26           | 130.09           | 137.69  | 134.69  | 131.75  | 127.47           |         |         |         |
| USD   | 119.48           | 120.08           | 122.54  | 119.74  | 120.52  | 112.43           |         |         |         |
| SGD   | 90.41            | 87.24            | 91.03   | 83.85   | 85.20   | 83.26            |         |         |         |

## Financial highlights (YTD)

(Billions of yen)

|                                      | Actual  | Actual |         |         |         | Actual |            |     |            |     |            |      |            |
|--------------------------------------|---------|--------|---------|---------|---------|--------|------------|-----|------------|-----|------------|------|------------|
|                                      | FY2014  | FY2015 |         |         |         | FY2016 |            |     |            |     |            |      |            |
|                                      | 1-12    | 1-3    | 1-6     | 1-9     | 1-12    | 1-3    | Change (%) | 1-6 | Change (%) | 1-9 | Change (%) | 1-12 | Change (%) |
|                                      | YTD     | YTD    | YTD     | YTD     | YTD     | YTD    |            | YTD |            | YTD |            | YTD  |            |
| Revenues                             | 461.1   | 117.1  | 240.2   | 367.8   | 498.8   | 119.9  | +2.4       |     |            |     |            |      |            |
| Sales                                | 436.9   | 113.4  | 232.6   | 353.3   | 468.4   | 115.6  | +1.9       |     |            |     |            |      |            |
| excl. Tamiflu                        | 423.8   | 106.7  | 225.9   | 346.5   | 460.2   | 108.6  | +1.8       |     |            |     |            |      |            |
| Domestic                             | 349.5   | 83.9   | 179.1   | 275.4   | 378.0   | 87.8   | +4.6       |     |            |     |            |      |            |
| Sales to Roche                       | 55.1    | 18.0   | 37.2    | 56.3    | 63.1    | 16.5   | (8.3)      |     |            |     |            |      |            |
| Overseas                             | 19.3    | 4.8    | 9.6     | 14.7    | 19.1    | 4.3    | (10.4)     |     |            |     |            |      |            |
| Tamiflu sales                        | 13.0    | 6.7    | 6.7     | 6.7     | 8.2     | 7.0    | +4.5       |     |            |     |            |      |            |
| Ordinary use                         | 12.9    | 6.7    | 6.7     | 6.7     | 8.2     | 7.0    | +4.5       |     |            |     |            |      |            |
| Govt. stockpiles etc.                | 0.2     | 0.0    | 0.0     | 0.0     | 0.0     | 0.0    | 0.0        |     |            |     |            |      |            |
| Royalties and other operating income | 24.2    | 3.7    | 7.5     | 14.5    | 30.4    | 4.3    | +16.2      |     |            |     |            |      |            |
| Cost of sales                        | (218.1) | (57.7) | (117.2) | (178.7) | (240.2) | (61.2) | +6.1       |     |            |     |            |      |            |
| (% of Sales)                         | 49.9    | 50.9   | 50.4    | 50.6    | 51.3    | 52.9   | -          |     |            |     |            |      |            |
| Gross profit                         | 243.0   | 59.3   | 122.9   | 189.0   | 258.6   | 58.7   | (1.0)      |     |            |     |            |      |            |
| (% of Revenues)                      | 52.7    | 50.6   | 51.2    | 51.4    | 51.8    | 49.0   | -          |     |            |     |            |      |            |
| Operating expenses                   | (167.2) | (38.6) | (79.7)  | (122.0) | (171.8) | (38.7) | +0.3       |     |            |     |            |      |            |
| (% of Revenues)                      | 36.3    | 33.0   | 33.2    | 33.2    | 34.4    | 32.3   | -          |     |            |     |            |      |            |
| Marketing and distribution           | (71.7)  | (16.6) | (34.7)  | (52.1)  | (74.8)  | (16.6) | 0.0        |     |            |     |            |      |            |
| (% of Revenues)                      | 15.5    | 14.2   | 14.4    | 14.2    | 15.0    | 13.8   | -          |     |            |     |            |      |            |
| Research and development             | (80.8)  | (19.0) | (39.2)  | (60.7)  | (83.8)  | (19.3) | +1.6       |     |            |     |            |      |            |
| (% of Revenues)                      | 17.5    | 16.2   | 16.3    | 16.5    | 16.8    | 16.1   | -          |     |            |     |            |      |            |
| General and administration           | (14.6)  | (3.0)  | (5.9)   | (9.1)   | (13.2)  | (2.8)  | (6.7)      |     |            |     |            |      |            |
| (% of Revenues)                      | 3.2     | 2.6    | 2.5     | 2.5     | 2.6     | 2.3    | -          |     |            |     |            |      |            |
| Operating profit                     | 75.9    | 20.7   | 43.2    | 67.1    | 86.8    | 20.1   | (2.9)      |     |            |     |            |      |            |
| (% of Revenues)                      | 16.5    | 17.7   | 18.0    | 18.2    | 17.4    | 16.8   | -          |     |            |     |            |      |            |
| Financing costs                      | (0.0)   | (0.0)  | (0.0)   | (0.1)   | (0.1)   | (0.0)  | 0.0        |     |            |     |            |      |            |
| Other financial income (expense)     | 0.3     | 0.5    | 0.7     | 0.4     | 0.6     | 0.1    | (80.0)     |     |            |     |            |      |            |
| Profit before taxes                  | 76.2    | 21.2   | 43.9    | 67.4    | 87.3    | 20.1   | (5.2)      |     |            |     |            |      |            |
| (% of Revenues)                      | 16.5    | 18.1   | 18.3    | 18.3    | 17.5    | 16.8   | -          |     |            |     |            |      |            |
| Income taxes                         | (24.1)  | (6.4)  | (13.1)  | (18.8)  | (24.9)  | (5.4)  | (15.6)     |     |            |     |            |      |            |
| Net income                           | 52.1    | 14.8   | 30.8    | 48.6    | 62.4    | 14.7   | (0.7)      |     |            |     |            |      |            |
| (% of Revenues)                      | 11.3    | 12.6   | 12.8    | 13.2    | 12.5    | 12.3   | -          |     |            |     |            |      |            |
| Attributable to                      |         |        |         |         |         |        |            |     |            |     |            |      |            |
| Chugai shareholders                  | 51.0    | 14.6   | 30.1    | 47.6    | 61.1    | 14.5   | (0.7)      |     |            |     |            |      |            |
| Non-controlling interests            | 1.1     | 0.2    | 0.7     | 0.9     | 1.2     | 0.2    | 0.0        |     |            |     |            |      |            |
| Earnings per share                   |         |        |         |         |         |        |            |     |            |     |            |      |            |
| Basic (yen)                          | 93.53   | 26.73  | 55.24   | 87.31   | 112.00  | 26.55  | (0.7)      |     |            |     |            |      |            |
| Diluted (yen)                        | 93.38   | 26.68  | 55.13   | 87.15   | 111.79  | 26.51  | (0.6)      |     |            |     |            |      |            |

Other financial income (expense) includes net amount of FX related gains/losses.

## Financial highlights (QTR)

(Billions of yen)

|                                      | Actual<br>FY2015 |        |        |        | Actual<br>FY2016 |               |     |               |     |               |       |               |
|--------------------------------------|------------------|--------|--------|--------|------------------|---------------|-----|---------------|-----|---------------|-------|---------------|
|                                      | 1-3              | 4-6    | 7-9    | 10-12  | 1-3              | Change<br>(%) | 4-6 | Change<br>(%) | 7-9 | Change<br>(%) | 10-12 | Change<br>(%) |
|                                      | QTR              | QTR    | QTR    | QTR    | QTR              |               | QTR |               | QTR |               | QTR   |               |
| Revenues                             | 117.1            | 123.1  | 127.6  | 131.1  | 119.9            | +2.4          |     |               |     |               |       |               |
| Sales                                | 113.4            | 119.2  | 120.6  | 115.2  | 115.6            | +1.9          |     |               |     |               |       |               |
| excl. Tamiflu                        | 106.7            | 119.2  | 120.6  | 113.7  | 108.6            | +1.8          |     |               |     |               |       |               |
| Domestic                             | 83.9             | 95.2   | 96.3   | 102.6  | 87.8             | +4.6          |     |               |     |               |       |               |
| Sales to Roche                       | 18.0             | 19.2   | 19.1   | 6.7    | 16.5             | (8.3)         |     |               |     |               |       |               |
| Overseas                             | 4.8              | 4.8    | 5.2    | 4.4    | 4.3              | (10.4)        |     |               |     |               |       |               |
| Tamiflu sales                        | 6.7              | 0.0    | 0.0    | 1.5    | 7.0              | +4.5          |     |               |     |               |       |               |
| Ordinary use                         | 6.7              | 0.0    | 0.0    | 1.5    | 7.0              | +4.5          |     |               |     |               |       |               |
| Govt. stockpiles etc.                | 0.0              | -      | -      | 0.0    | 0.0              | 0.0           |     |               |     |               |       |               |
| Royalties and other operating income | 3.7              | 3.9    | 7.0    | 15.9   | 4.3              | +16.2         |     |               |     |               |       |               |
| Cost of sales                        | (57.7)           | (59.5) | (61.5) | (61.5) | (61.2)           | +6.1          |     |               |     |               |       |               |
| (% of Sales)                         | 50.9             | 49.9   | 51.0   | 53.4   | 52.9             | -             |     |               |     |               |       |               |
| Gross profit                         | 59.3             | 63.6   | 66.1   | 69.6   | 58.7             | (1.0)         |     |               |     |               |       |               |
| (% of Revenues)                      | 50.6             | 51.7   | 51.8   | 53.1   | 49.0             | -             |     |               |     |               |       |               |
| Operating expenses                   | (38.6)           | (41.1) | (42.3) | (49.8) | (38.7)           | +0.3          |     |               |     |               |       |               |
| (% of Revenues)                      | 33.0             | 33.4   | 33.2   | 38.0   | 32.3             | -             |     |               |     |               |       |               |
| Marketing and distribution           | (16.6)           | (18.1) | (17.5) | (22.7) | (16.6)           | 0.0           |     |               |     |               |       |               |
| (% of Revenues)                      | 14.2             | 14.7   | 13.7   | 17.3   | 13.8             | -             |     |               |     |               |       |               |
| Research and development             | (19.0)           | (20.2) | (21.5) | (23.1) | (19.3)           | +1.6          |     |               |     |               |       |               |
| (% of Revenues)                      | 16.2             | 16.4   | 16.8   | 17.6   | 16.1             | -             |     |               |     |               |       |               |
| General and administration           | (3.0)            | (2.9)  | (3.3)  | (4.1)  | (2.8)            | (6.7)         |     |               |     |               |       |               |
| (% of Revenues)                      | 2.6              | 2.4    | 2.6    | 3.1    | 2.3              | -             |     |               |     |               |       |               |
| Operating profit                     | 20.7             | 22.5   | 23.8   | 19.7   | 20.1             | (2.9)         |     |               |     |               |       |               |
| (% of Revenues)                      | 17.7             | 18.3   | 18.7   | 15.0   | 16.8             | -             |     |               |     |               |       |               |
| Financing costs                      | (0.0)            | (0.0)  | (0.0)  | (0.0)  | (0.0)            | 0.0           |     |               |     |               |       |               |
| Other financial income (expense)     | 0.5              | 0.2    | (0.3)  | 0.2    | 0.1              | (80.0)        |     |               |     |               |       |               |
| Profit before taxes                  | 21.2             | 22.7   | 23.5   | 19.9   | 20.1             | (5.2)         |     |               |     |               |       |               |
| (% of Revenues)                      | 18.1             | 18.4   | 18.4   | 15.2   | 16.8             | -             |     |               |     |               |       |               |
| Income taxes                         | (6.4)            | (6.7)  | (5.7)  | (6.1)  | (5.4)            | (15.6)        |     |               |     |               |       |               |
| Net income                           | 14.8             | 16.0   | 17.8   | 13.8   | 14.7             | (0.7)         |     |               |     |               |       |               |
| (% of Revenues)                      | 12.6             | 13.0   | 13.9   | 10.5   | 12.3             | -             |     |               |     |               |       |               |
| Attributable to                      |                  |        |        |        |                  |               |     |               |     |               |       |               |
| Chugai shareholders                  | 14.6             | 15.6   | 17.5   | 13.5   | 14.5             | (0.7)         |     |               |     |               |       |               |
| Non-controlling interests            | 0.2              | 0.4    | 0.3    | 0.3    | 0.2              | 0.0           |     |               |     |               |       |               |
| Earnings per share                   |                  |        |        |        |                  |               |     |               |     |               |       |               |
| Basic (yen)                          | 26.73            | 28.51  | 32.07  | 24.69  | 26.55            | (0.7)         |     |               |     |               |       |               |
| Diluted (yen)                        | 26.68            | 28.45  | 32.01  | 24.65  | 26.51            | (0.6)         |     |               |     |               |       |               |

Other financial income (expense) includes net amount of FX related gains/losses.

## Financial highlights (Core results YTD)

(Billions of yen)

|  | Actual  | Actual |         |         |         | Actual |            |     |            |     |            | Forecast             |            |         |            |
|--|---------|--------|---------|---------|---------|--------|------------|-----|------------|-----|------------|----------------------|------------|---------|------------|
|  | FY2014  | FY2015 |         |         |         | FY2016 |            |     |            |     |            | (Jan 28th Announced) |            |         |            |
|  | 1-12    | 1-3    | 1-6     | 1-9     | 1-12    | 1-3    | Change (%) | 1-6 | Change (%) | 1-9 | Change (%) | 1-12                 | Change (%) | 1-12    | Change (%) |
|  | YTD     | YTD    | YTD     | YTD     | YTD     | YTD    |            | YTD |            | YTD |            | YTD                  |            | YTD     |            |
| Revenues   | 461.1   | 117.1  | 240.2   | 367.8   | 498.8   | 119.9  | +2.4       |     |            |     |            |                      |            | 495.0   | (0.8)      |
| Sales  | 436.9   | 113.4  | 232.6   | 353.3   | 468.4   | 115.6  | +1.9       |     |            |     |            |                      |            | 475.4   | +1.5       |
| excl. Tamiflu  | 423.8   | 106.7  | 225.9   | 346.5   | 460.2   | 108.6  | +1.8       |     |            |     |            |                      |            | 466.8   | +1.4       |
| Domestic   | 349.5   | 83.9   | 179.1   | 275.4   | 378.0   | 87.8   | +4.6       |     |            |     |            |                      |            | 379.0   | +0.3       |
| Sales to Roche   | 55.1    | 18.0   | 37.2    | 56.3    | 63.1    | 16.5   | (8.3)      |     |            |     |            |                      |            | 70.5    | +11.7      |
| Overseas   | 19.3    | 4.8    | 9.6     | 14.7    | 19.1    | 4.3    | (10.4)     |     |            |     |            |                      |            | 17.3    | (9.4)      |
| Tamiflu sales  | 13.0    | 6.7    | 6.7     | 6.7     | 8.2     | 7.0    | +4.5       |     |            |     |            |                      |            | 8.6     | +4.9       |
| Ordinary use   | 12.9    | 6.7    | 6.7     | 6.7     | 8.2     | 7.0    | +4.5       |     |            |     |            |                      |            | 7.6     | (7.3)      |
| Govt. stockpiles etc.  | 0.2     | 0.0    | 0.0     | 0.0     | 0.0     | 0.0    | 0.0        |     |            |     |            |                      |            | 1.0     | -          |
| Royalties and other operating income   | 24.2    | 3.7    | 7.5     | 14.5    | 30.4    | 4.3    | +16.2      |     |            |     |            |                      |            | 19.6    | (35.5)     |
| Cost of sales  | (217.0) | (57.4) | (116.6) | (177.7) | (238.9) | (60.9) | +6.1       |     |            |     |            |                      |            | (254.0) | +6.3       |
| (% of Sales)   | 49.7    | 50.6   | 50.1    | 50.3    | 51.0    | 52.7   | -          |     |            |     |            |                      |            | 53.4    | -          |
| Gross profit   | 244.2   | 59.7   | 123.6   | 190.1   | 260.0   | 59.0   | (1.2)      |     |            |     |            |                      |            | 241.0   | (7.3)      |
| (% of Revenues)  | 53.0    | 51.0   | 51.5    | 51.7    | 52.1    | 49.2   | -          |     |            |     |            |                      |            | 48.7    | -          |
| Operating expenses   | (166.8) | (38.2) | (77.7)  | (119.8) | (169.3) | (38.6) | +1.0       |     |            |     |            |                      |            | (170.0) | +0.4       |
| (% of Revenues)  | 36.2    | 32.6   | 32.3    | 32.6    | 33.9    | 32.2   | -          |     |            |     |            |                      |            | 34.3    | -          |
| Marketing and distribution   | (71.7)  | (16.6) | (34.6)  | (52.0)  | (74.7)  | (16.5) | (0.6)      |     |            |     |            |                      |            |         |            |
| (% of Revenues)  | 15.5    | 14.2   | 14.4    | 14.1    | 15.0    | 13.8   | -          |     |            |     |            |                      |            |         |            |
| Research and development   | (80.6)  | (18.6) | (37.3)  | (58.8)  | (81.9)  | (19.2) | +3.2       |     |            |     |            |                      |            |         |            |
| (% of Revenues)  | 17.5    | 15.9   | 15.5    | 16.0    | 16.4    | 16.0   | -          |     |            |     |            |                      |            |         |            |
| General and administration   | (14.6)  | (3.0)  | (5.8)   | (8.9)   | (12.8)  | (2.8)  | (6.7)      |     |            |     |            |                      |            |         |            |
| (% of Revenues)  | 3.2     | 2.6    | 2.4     | 2.4     | 2.6     | 2.3    | -          |     |            |     |            |                      |            |         |            |
| Operating profit   | 77.3    | 21.5   | 45.9    | 70.3    | 90.7    | 20.4   | (5.1)      |     |            |     |            |                      |            | 71.0    | (21.7)     |
| (% of Revenues)  | 16.8    | 18.4   | 19.1    | 19.1    | 18.2    | 17.0   | -          |     |            |     |            |                      |            | 14.3    | -          |
| Financing costs  | (0.0)   | (0.0)  | (0.0)   | (0.1)   | (0.1)   | (0.0)  | 0.0        |     |            |     |            |                      |            |         |            |
| Other financial income (expense)   | 0.3     | 0.5    | 0.7     | 0.4     | 0.6     | 0.1    | (80.0)     |     |            |     |            |                      |            |         |            |
| Profit before taxes  | 77.6    | 21.9   | 46.5    | 70.6    | 91.2    | 20.5   | (6.4)      |     |            |     |            |                      |            |         |            |
| (% of Revenues)  | 16.8    | 18.7   | 19.4    | 19.2    | 18.3    | 17.1   | -          |     |            |     |            |                      |            |         |            |
| Income taxes   | (24.6)  | (6.6)  | (14.0)  | (20.0)  | (26.3)  | (5.6)  | (15.2)     |     |            |     |            |                      |            |         |            |
| Net income   | 53.0    | 15.3   | 32.5    | 50.7    | 64.9    | 14.9   | (2.6)      |     |            |     |            |                      |            |         |            |
| (% of Revenues)  | 11.5    | 13.1   | 13.5    | 13.8    | 13.0    | 12.4   | -          |     |            |     |            |                      |            |         |            |
| Attributable to  |         |        |         |         |         |        |            |     |            |     |            |                      |            |         |            |
| Chugai shareholders  | 51.9    | 15.1   | 31.9    | 49.8    | 63.7    | 14.7   | (2.6)      |     |            |     |            |                      |            |         |            |
| Non-controlling interests  | 1.1     | 0.2    | 0.7     | 0.9     | 1.2     | 0.2    | 0.0        |     |            |     |            |                      |            |         |            |
| Weighted average number of shares in issue used to calculate diluted earnings per share (Millions of shares) | 546     | 547    | 547     | 547     | 547     | 547    | 0.0        |     |            |     |            |                      |            |         |            |
| Core earnings per share (diluted) (yen)  | 95.04   | 27.54  | 58.30   | 91.01   | 116.42  | 26.94  | (2.2)      |     |            |     |            |                      |            | 92.54   | (20.5)     |
| Core payout ratio (%)  | 50.5    |        |         |         | 49.8    |        |            |     |            |     |            |                      |            | 56.2    | -          |
| Dividend per share (Full year) (yen)   | 48      |        |         |         | 58      |        |            |     |            |     |            |                      |            | 52      | -          |
| Dividend per share (Half year) (yen)   | 22      |        |         |         | 26      |        |            |     |            |     |            |                      |            | 26      | -          |

Please see page 5 "Reconciliation of IFRS results to Core results" for the detail of the adjustments.

Core earnings per share (diluted) (yen) : Net income attributable to Chugai shareholders / Weighted average number of shares in issue used to calculate diluted earnings per share.

Other financial income (expense) includes net amount of FX related gains/losses.

## Financial highlights (Core results QTR)

(Billions of yen)

|   | Actual |        |        |        | Actual |            |     |            |     |            |       |            |
|---|--------|--------|--------|--------|--------|------------|-----|------------|-----|------------|-------|------------|
|   | FY2015 |        |        |        | FY2016 |            |     |            |     |            |       |            |
|   | 1-3    | 4-6    | 7-9    | 10-12  | 1-3    | Change (%) | 4-6 | Change (%) | 7-9 | Change (%) | 10-12 | Change (%) |
|   | QTR    | QTR    | QTR    | QTR    | QTR    |            | QTR |            | QTR |            | QTR   |            |
| Revenues                                | 117.1  | 123.1  | 127.6  | 131.1  | 119.9  | +2.4       |     |            |     |            |       |            |
| Sales                                   | 113.4  | 119.2  | 120.6  | 115.2  | 115.6  | +1.9       |     |            |     |            |       |            |
| excl. Tamiflu                           | 106.7  | 119.2  | 120.6  | 113.7  | 108.6  | +1.8       |     |            |     |            |       |            |
| Domestic                                | 83.9   | 95.2   | 96.3   | 102.6  | 87.8   | +4.6       |     |            |     |            |       |            |
| Sales to Roche                          | 18.0   | 19.2   | 19.1   | 6.7    | 16.5   | (8.3)      |     |            |     |            |       |            |
| Overseas                                | 4.8    | 4.8    | 5.2    | 4.4    | 4.3    | (10.4)     |     |            |     |            |       |            |
| Tamiflu sales                           | 6.7    | 0.0    | 0.0    | 1.5    | 7.0    | +4.5       |     |            |     |            |       |            |
| Ordinary use                            | 6.7    | 0.0    | 0.0    | 1.5    | 7.0    | +4.5       |     |            |     |            |       |            |
| Govt. stockpiles etc.                   | 0.0    | -      | -      | 0.0    | 0.0    | 0.0        |     |            |     |            |       |            |
| Royalties and other operating income    | 3.7    | 3.9    | 7.0    | 15.9   | 4.3    | +16.2      |     |            |     |            |       |            |
| Cost of sales                           | (57.4) | (59.1) | (61.1) | (61.2) | (60.9) | +6.1       |     |            |     |            |       |            |
| (% of Sales)                            | 50.6   | 49.6   | 50.7   | 53.1   | 52.7   | -          |     |            |     |            |       |            |
| Gross profit                            | 59.7   | 63.9   | 66.5   | 69.9   | 59.0   | (1.2)      |     |            |     |            |       |            |
| (% of Revenues)                         | 51.0   | 51.9   | 52.1   | 53.3   | 49.2   | -          |     |            |     |            |       |            |
| Operating expenses                      | (38.2) | (39.5) | (42.0) | (49.5) | (38.6) | +1.0       |     |            |     |            |       |            |
| (% of Revenues)                         | 32.6   | 32.1   | 32.9   | 37.8   | 32.2   | -          |     |            |     |            |       |            |
| Marketing and distribution              | (16.6) | (18.0) | (17.4) | (22.6) | (16.5) | (0.6)      |     |            |     |            |       |            |
| (% of Revenues)                         | 14.2   | 14.6   | 13.6   | 17.2   | 13.8   | -          |     |            |     |            |       |            |
| Research and development                | (18.6) | (18.7) | (21.5) | (23.1) | (19.2) | +3.2       |     |            |     |            |       |            |
| (% of Revenues)                         | 15.9   | 15.2   | 16.8   | 17.6   | 16.0   | -          |     |            |     |            |       |            |
| General and administration              | (3.0)  | (2.8)  | (3.1)  | (3.8)  | (2.8)  | (6.7)      |     |            |     |            |       |            |
| (% of Revenues)                         | 2.6    | 2.3    | 2.4    | 2.9    | 2.3    | -          |     |            |     |            |       |            |
| Operating profit                        | 21.5   | 24.4   | 24.4   | 20.4   | 20.4   | (5.1)      |     |            |     |            |       |            |
| (% of Revenues)                         | 18.4   | 19.8   | 19.1   | 15.6   | 17.0   | -          |     |            |     |            |       |            |
| Financing costs                         | (0.0)  | (0.0)  | (0.0)  | (0.0)  | (0.0)  | 0.0        |     |            |     |            |       |            |
| Other financial income (expense)        | 0.5    | 0.2    | (0.3)  | 0.2    | 0.1    | (80.0)     |     |            |     |            |       |            |
| Profit before taxes                     | 21.9   | 24.6   | 24.1   | 20.5   | 20.5   | (6.4)      |     |            |     |            |       |            |
| (% of Revenues)                         | 18.7   | 20.0   | 18.9   | 15.6   | 17.1   | -          |     |            |     |            |       |            |
| Income taxes                            | (6.6)  | (7.4)  | (6.0)  | (6.3)  | (5.6)  | (15.2)     |     |            |     |            |       |            |
| Net income                              | 15.3   | 17.2   | 18.2   | 14.2   | 14.9   | (2.6)      |     |            |     |            |       |            |
| (% of Revenues)                         | 13.1   | 14.0   | 14.3   | 10.8   | 12.4   | -          |     |            |     |            |       |            |
| Attributable to                         |        |        |        |        |        |            |     |            |     |            |       |            |
| Chugai shareholders                     | 15.1   | 16.8   | 17.9   | 13.9   | 14.7   | (2.6)      |     |            |     |            |       |            |
| Non-controlling interests               | 0.2    | 0.4    | 0.3    | 0.3    | 0.2    | 0.0        |     |            |     |            |       |            |
| Core earnings per share (diluted) (yen) | 27.54  | 30.76  | 32.71  | 25.42  | 26.94  | (2.2)      |     |            |     |            |       |            |

Other financial income (expense) includes net amount of FX related gains/losses.

**Reconciliation of IFRS results to Core results**

(Billions of yen)

|                                      | FY2015       |                   |        |              | FY2016       |                   |        |              |
|--------------------------------------|--------------|-------------------|--------|--------------|--------------|-------------------|--------|--------------|
|                                      | 1-3          |                   |        |              | 1-3          |                   |        |              |
|                                      | IFRS results | Intangible assets | Others | Core results | IFRS results | Intangible assets | Others | Core results |
| Revenues                             | 117.1        | –                 | –      | 117.1        | 119.9        | –                 | –      | 119.9        |
| Sales                                | 113.4        | –                 | –      | 113.4        | 115.6        | –                 | –      | 115.6        |
| Royalties and other operating income | 3.7          | –                 | –      | 3.7          | 4.3          | –                 | –      | 4.3          |
| Cost of sales                        | (57.7)       | 0.3               | –      | (57.4)       | (61.2)       | 0.3               | –      | (60.9)       |
| Gross profit                         | 59.3         | 0.3               | –      | 59.7         | 58.7         | 0.3               | –      | 59.0         |
| Operating expenses                   | (38.6)       | 0.4               | 0.1    | (38.2)       | (38.7)       | 0.1               | –      | (38.6)       |
| Marketing and distribution           | (16.6)       | 0.0               | –      | (16.6)       | (16.6)       | 0.0               | –      | (16.5)       |
| Research and development             | (19.0)       | 0.3               | –      | (18.6)       | (19.3)       | 0.0               | –      | (19.2)       |
| General and administration           | (3.0)        | –                 | 0.1    | (3.0)        | (2.8)        | –                 | –      | (2.8)        |
| Operating profit                     | 20.7         | 0.7               | 0.1    | 21.5         | 20.1         | 0.4               | –      | 20.4         |
| Financing costs                      | (0.0)        | –                 | –      | (0.0)        | (0.0)        | –                 | –      | (0.0)        |
| Other financial income (expense)     | 0.5          | –                 | –      | 0.5          | 0.1          | –                 | –      | 0.1          |
| Profit before taxes                  | 21.2         | 0.7               | 0.1    | 21.9         | 20.1         | 0.4               | –      | 20.5         |
| Income taxes                         | (6.4)        | (0.2)             | (0.0)  | (6.6)        | (5.4)        | (0.1)             | –      | (5.6)        |
| Net income                           | 14.8         | 0.4               | 0.0    | 15.3         | 14.7         | 0.2               | –      | 14.9         |
| Attributable to                      |              |                   |        |              |              |                   |        |              |
| Chugai shareholders                  | 14.6         | 0.4               | 0.0    | 15.1         | 14.5         | 0.2               | –      | 14.7         |
| Non-controlling interests            | 0.2          | –                 | –      | 0.2          | 0.2          | –                 | –      | 0.2          |

**Core results**

Chugai discloses its results on a Core basis from 2013 in conjunction with its decision to apply IFRS. Core results are the results after adjusting non-Core items to IFRS results, and are consistent with the Core concept disclosed by Roche. Core results are used by Chugai as an internal performance indicator, for explaining the underlying business performance both internally and externally, and as the basis for payment-by-results such as a return to shareholders.

The table above shows the reconciliation of IFRS results into Core results. The detail is as below.

**Intangible assets**

Amortization of intangible assets (0.4 billion yen in 2015 and 0.4 billion yen in 2016)

Impairment of intangible assets (0.3 billion yen in 2015 and none in 2016)

**Others**

Restructuring expenses (none in 2015 and 2016)

Environmental costs (0.1 billion yen in 2015 and none in 2016)

## Statements of revenues (YTD)

(Billions of yen)

|   | Actual | Actual |       |       |       | Actual |            |     |            |     |            | Forecast<br>(Jan 28th announced) |            |           |            |
|---|--------|--------|-------|-------|-------|--------|------------|-----|------------|-----|------------|----------------------------------|------------|-----------|------------|
|   | FY2014 | FY2015 |       |       |       | FY2016 |            |     |            |     |            | FY2016                           |            |           |            |
|   | 1-12   | 1-3    | 1-6   | 1-9   | 1-12  | 1-3    | Change (%) | 1-6 | Change (%) | 1-9 | Change (%) | 1-12                             | Change (%) | 1-12      | Change (%) |
|   | YTD    | YTD    | YTD   | YTD   | YTD   | YTD    |            | YTD |            | YTD |            | YTD                              |            | Full-year |            |
| Sales   | 436.9  | 113.4  | 232.6 | 353.3 | 468.4 | 115.6  | +1.9       |     |            |     |            |                                  |            | 475.4     | +1.5       |
| Excl. Tamiflu                                   | 423.8  | 106.7  | 225.9 | 346.5 | 460.2 | 108.6  | +1.8       |     |            |     |            |                                  |            | 466.8     | +1.4       |
| Domestic  | 349.5  | 83.9   | 179.1 | 275.4 | 378.0 | 87.8   | +4.6       |     |            |     |            |                                  |            | 379.0     | +0.3       |
| Oncology  | 188.9  | 47.7   | 101.8 | 156.9 | 215.7 | 51.1   | +7.1       |     |            |     |            |                                  |            | 220.3     | +2.1       |
| Avastin   | 82.3   | 20.9   | 44.3  | 68.2  | 93.8  | 22.3   | +6.7       |     |            |     |            |                                  |            | 93.4      | (0.4)      |
| Herceptin                                       | 31.2   | 7.5    | 15.8  | 24.1  | 32.7  | 7.8    | +4.0       |     |            |     |            |                                  |            | 34.9      | +6.7       |
| Rituxan   | 26.2   | 6.4    | 13.6  | 21.0  | 29.0  | 7.2    | +12.5      |     |            |     |            |                                  |            | 32.9      | +13.4      |
| Xeloda  | 10.4   | 2.6    | 5.3   | 8.1   | 11.1  | 2.9    | +11.5      |     |            |     |            |                                  |            | 12.6      | +13.5      |
| Tarceva   | 11.5   | 2.5    | 5.5   | 8.6   | 11.6  | 2.5    | 0.0        |     |            |     |            |                                  |            | 12.5      | +7.8       |
| Perjeta   | 9.1    | 2.3    | 5.0   | 7.8   | 10.6  | 2.7    | +17.4      |     |            |     |            |                                  |            | 11.3      | +6.6       |
| Alecensa  | 1.4    | 1.3    | 3.1   | 5.1   | 8.0   | 2.2    | +69.2      |     |            |     |            |                                  |            | 9.6       | +20.0      |
| Kadcyla   | 4.0    | 1.5    | 3.4   | 5.3   | 7.3   | 1.9    | +26.7      |     |            |     |            |                                  |            | 7.6       | +4.1       |
| Neutrogin                                       | 5.9    | 1.0    | 2.3   | 3.6   | 4.9   | 0.8    | (20.0)     |     |            |     |            |                                  |            | 2.9       | (40.8)     |
| Zelboraf  | -      | 0.1    | 0.2   | 0.3   | 0.5   | 0.1    | 0.0        |     |            |     |            |                                  |            | 0.7       | +40.0      |
| Other products                                  | 6.9    | 1.6    | 3.3   | 4.7   | 6.1   | 0.5    | (68.8)     |     |            |     |            |                                  |            | 1.8       | (70.5)     |
| Bone and joint diseases                         | 69.6   | 17.6   | 37.5  | 57.5  | 79.4  | 19.8   | +12.5      |     |            |     |            |                                  |            | 85.8      | +8.1       |
| Actemra   | 24.1   | 5.9    | 12.6  | 19.4  | 26.8  | 6.6    | +11.9      |     |            |     |            |                                  |            | 29.7      | +10.8      |
| Ediol   | 19.2   | 4.9    | 10.6  | 16.4  | 23.1  | 5.8    | +18.4      |     |            |     |            |                                  |            | 25.6      | +10.8      |
| Suvenyl   | 10.7   | 2.3    | 5.1   | 7.7   | 10.5  | 2.2    | (4.3)      |     |            |     |            |                                  |            | 9.5       | (9.5)      |
| Bonviva   | 3.4    | 1.1    | 2.4   | 3.8   | 5.4   | 1.5    | +36.4      |     |            |     |            |                                  |            | 7.7       | +42.6      |
| Alfarol   | 4.9    | 1.0    | 2.1   | 3.1   | 4.2   | 0.8    | (20.0)     |     |            |     |            |                                  |            | 3.1       | (26.2)     |
| Other products                                  | 7.4    | 2.4    | 4.7   | 7.0   | 9.5   | 2.9    | +20.8      |     |            |     |            |                                  |            | 10.2      | +7.4       |
| Renal diseases                                  | 44.7   | 9.9    | 21.4  | 33.1  | 45.4  | 9.6    | (3.0)      |     |            |     |            |                                  |            | 40.8      | (10.1)     |
| Mircera   | 22.6   | 5.0    | 11.0  | 17.1  | 23.8  | 5.3    | +6.0       |     |            |     |            |                                  |            | 23.7      | (0.4)      |
| Oxarol  | 12.2   | 2.8    | 6.0   | 9.4   | 12.9  | 2.4    | (14.3)     |     |            |     |            |                                  |            | 9.2       | (28.7)     |
| Epogin  | 6.6    | 1.4    | 2.9   | 4.4   | 5.9   | 1.2    | (14.3)     |     |            |     |            |                                  |            | 5.3       | (10.2)     |
| Other products                                  | 3.4    | 0.7    | 1.4   | 2.1   | 2.8   | 0.6    | (14.3)     |     |            |     |            |                                  |            | 2.5       | (10.7)     |
| Transplant, Immunology, and Infectious diseases | 20.8   | 3.4    | 7.1   | 11.5  | 15.9  | 3.2    | (5.9)      |     |            |     |            |                                  |            | 14.1      | (11.3)     |
| CellCept  | 6.5    | 1.6    | 3.3   | 5.0   | 7.0   | 1.7    | +6.3       |     |            |     |            |                                  |            | 8.1       | +15.7      |
| Copegus   | 3.1    | 0.2    | 0.6   | 1.8   | 2.9   | 0.5    | +150.0     |     |            |     |            |                                  |            | 1.5       | (48.3)     |
| Pegasys   | 7.0    | 0.8    | 1.3   | 1.7   | 1.9   | 0.1    | (87.5)     |     |            |     |            |                                  |            | 0.9       | (52.6)     |
| Other products                                  | 4.2    | 0.9    | 2.0   | 3.0   | 4.0   | 0.8    | (11.1)     |     |            |     |            |                                  |            | 3.6       | (10.0)     |
| Others  | 25.6   | 5.3    | 11.4  | 16.5  | 21.7  | 4.1    | (22.6)     |     |            |     |            |                                  |            | 18.0      | (17.1)     |
| Sigmart   | 6.4    | 1.3    | 2.6   | 3.9   | 5.2   | 1.0    | (23.1)     |     |            |     |            |                                  |            | 4.0       | (23.1)     |
| Other products                                  | 19.2   | 4.0    | 8.8   | 12.6  | 16.6  | 3.2    | (20.0)     |     |            |     |            |                                  |            | 14.0      | (15.7)     |
| Overseas  | 74.3   | 22.8   | 46.8  | 71.1  | 82.2  | 20.8   | (8.8)      |     |            |     |            |                                  |            | 87.8      | +6.8       |
| Actemra   | 55.7   | 18.3   | 37.7  | 56.9  | 63.6  | 16.1   | (12.0)     |     |            |     |            |                                  |            | 69.3      | +9.0       |
| To Roche  | 55.1   | 18.0   | 37.2  | 56.1  | 62.6  | 15.8   | (12.2)     |     |            |     |            |                                  |            | 68.0      | +8.6       |
| Neutrogin                                       | 15.7   | 3.7    | 7.4   | 11.4  | 14.8  | 3.1    | (16.2)     |     |            |     |            |                                  |            | 13.1      | (11.5)     |
| Alecensa  | -      | -      | -     | 0.2   | 0.5   | 0.7    | -          |     |            |     |            |                                  |            | 2.5       | +400.0     |
| Akyneo  | -      | -      | -     | 0.0   | 0.0   | 0.0    | -          |     |            |     |            |                                  |            | 0.2       | -          |
| Aloxi   | -      | 0.1    | 0.1   | 0.2   | 0.3   | 0.1    | 0.0        |     |            |     |            |                                  |            | 0.1       | (66.7)     |
| Other products                                  | 2.9    | 0.8    | 1.6   | 2.4   | 3.0   | 0.8    | 0.0        |     |            |     |            |                                  |            | 2.6       | (13.3)     |
| Tamiflu   | 13.0   | 6.7    | 6.7   | 6.7   | 8.2   | 7.0    | +4.5       |     |            |     |            |                                  |            | 8.6       | +4.9       |
| Ordinary use                                    | 12.9   | 6.7    | 6.7   | 6.7   | 8.2   | 7.0    | +4.5       |     |            |     |            |                                  |            | 7.6       | (7.3)      |
| Govt. stockpiles etc.                           | 0.2    | 0.0    | 0.0   | 0.0   | 0.0   | 0.0    | 0.0        |     |            |     |            |                                  |            | 1.0       | -          |
| Royalties and other operating income            | 24.2   | 3.7    | 7.5   | 14.5  | 30.4  | 4.3    | +16.2      |     |            |     |            |                                  |            | 19.6      | (35.5)     |
| Revenues  | 461.1  | 117.1  | 240.2 | 367.8 | 498.8 | 119.9  | +2.4       |     |            |     |            |                                  |            | 495.0     | (0.8)      |
| Domestic  | 372.9  | 90.8   | 186.2 | 282.6 | 390.0 | 95.2   | +4.8       |     |            |     |            |                                  |            | 389.5     | (0.1)      |
| Overseas  | 88.2   | 26.2   | 53.9  | 85.1  | 108.8 | 24.7   | (5.7)      |     |            |     |            |                                  |            | 105.5     | (3.0)      |



## Statements of revenues (QTR)

(Billions of yen)

|   | Actual |       |       |       | Actual |            |     |            |     |            |       |            |
|---|--------|-------|-------|-------|--------|------------|-----|------------|-----|------------|-------|------------|
|   | FY2015 |       |       |       | FY2016 |            |     |            |     |            |       |            |
|   | 1-3    | 4-6   | 7-9   | 10-12 | 1-3    | Change (%) | 4-6 | Change (%) | 7-9 | Change (%) | 10-12 | Change (%) |
|   | QTR    | QTR   | QTR   | QTR   | QTR    |            | QTR |            | QTR |            | QTR   |            |
| Sales   | 113.4  | 119.2 | 120.6 | 115.2 | 115.6  | +1.9       |     |            |     |            |       |            |
| Excl. Tamiflu                                   | 106.7  | 119.2 | 120.6 | 113.7 | 108.6  | +1.8       |     |            |     |            |       |            |
| Domestic  | 83.9   | 95.2  | 96.3  | 102.6 | 87.8   | +4.6       |     |            |     |            |       |            |
| Oncology  | 47.7   | 54.1  | 55.1  | 58.8  | 51.1   | +7.1       |     |            |     |            |       |            |
| Avastin   | 20.9   | 23.4  | 23.9  | 25.6  | 22.3   | +6.7       |     |            |     |            |       |            |
| Herceptin                                       | 7.5    | 8.4   | 8.3   | 8.6   | 7.8    | +4.0       |     |            |     |            |       |            |
| Rituxan   | 6.4    | 7.2   | 7.4   | 7.9   | 7.2    | +12.5      |     |            |     |            |       |            |
| Xeloda  | 2.6    | 2.8   | 2.8   | 3.0   | 2.9    | +11.5      |     |            |     |            |       |            |
| Tarceva   | 2.5    | 3.0   | 3.1   | 3.0   | 2.5    | 0.0        |     |            |     |            |       |            |
| Perjeta   | 2.3    | 2.7   | 2.8   | 2.8   | 2.7    | +17.4      |     |            |     |            |       |            |
| Alecensa  | 1.3    | 1.7   | 2.1   | 2.8   | 2.2    | +69.2      |     |            |     |            |       |            |
| Kadcyla   | 1.5    | 1.9   | 1.9   | 2.0   | 1.9    | +26.7      |     |            |     |            |       |            |
| Neutrogin                                       | 1.0    | 1.3   | 1.3   | 1.3   | 0.8    | (20.0)     |     |            |     |            |       |            |
| Zelboraf  | 0.1    | 0.1   | 0.2   | 0.2   | 0.1    | 0.0        |     |            |     |            |       |            |
| Other products                                  | 1.6    | 1.7   | 1.4   | 1.4   | 0.5    | (68.8)     |     |            |     |            |       |            |
| Bone and joint diseases                         | 17.6   | 19.8  | 20.1  | 21.8  | 19.8   | +12.5      |     |            |     |            |       |            |
| Actemra   | 5.9    | 6.7   | 6.8   | 7.4   | 6.6    | +11.9      |     |            |     |            |       |            |
| Edirol  | 4.9    | 5.7   | 5.8   | 6.6   | 5.8    | +18.4      |     |            |     |            |       |            |
| Suvenyl   | 2.3    | 2.7   | 2.6   | 2.8   | 2.2    | (4.3)      |     |            |     |            |       |            |
| Bonviva   | 1.1    | 1.3   | 1.4   | 1.6   | 1.5    | +36.4      |     |            |     |            |       |            |
| Alfarol   | 1.0    | 1.1   | 1.0   | 1.1   | 0.8    | (20.0)     |     |            |     |            |       |            |
| Other products                                  | 2.4    | 2.3   | 2.3   | 2.4   | 2.9    | +20.8      |     |            |     |            |       |            |
| Renal diseases                                  | 9.9    | 11.5  | 11.7  | 12.3  | 9.6    | (3.0)      |     |            |     |            |       |            |
| Mircera   | 5.0    | 6.0   | 6.1   | 6.7   | 5.3    | +6.0       |     |            |     |            |       |            |
| Oxarol  | 2.8    | 3.2   | 3.4   | 3.5   | 2.4    | (14.3)     |     |            |     |            |       |            |
| Epogin  | 1.4    | 1.5   | 1.5   | 1.5   | 1.2    | (14.3)     |     |            |     |            |       |            |
| Other products                                  | 0.7    | 0.7   | 0.7   | 0.7   | 0.6    | (14.3)     |     |            |     |            |       |            |
| Transplant, Immunology, and Infectious diseases | 3.4    | 3.7   | 4.3   | 4.4   | 3.2    | (5.9)      |     |            |     |            |       |            |
| CellCept  | 1.6    | 1.7   | 1.8   | 1.9   | 1.7    | +6.3       |     |            |     |            |       |            |
| Copegus   | 0.2    | 0.4   | 1.2   | 1.2   | 0.5    | +150.0     |     |            |     |            |       |            |
| Pegasys   | 0.8    | 0.6   | 0.4   | 0.2   | 0.1    | (87.5)     |     |            |     |            |       |            |
| Other products                                  | 0.9    | 1.0   | 1.0   | 1.1   | 0.8    | (11.1)     |     |            |     |            |       |            |
| Others  | 5.3    | 6.1   | 5.1   | 5.2   | 4.1    | (22.6)     |     |            |     |            |       |            |
| Sigmart   | 1.3    | 1.3   | 1.3   | 1.3   | 1.0    | (23.1)     |     |            |     |            |       |            |
| Other products                                  | 4.0    | 4.8   | 3.8   | 3.9   | 3.2    | (20.0)     |     |            |     |            |       |            |
| Overseas  | 22.8   | 24.0  | 24.3  | 11.1  | 20.8   | (8.8)      |     |            |     |            |       |            |
| Actemra   | 18.3   | 19.4  | 19.2  | 6.7   | 16.1   | (12.0)     |     |            |     |            |       |            |
| To Roche  | 18.0   | 19.2  | 18.9  | 6.5   | 15.8   | (12.2)     |     |            |     |            |       |            |
| Neutrogin                                       | 3.7    | 3.7   | 4.0   | 3.5   | 3.1    | (16.2)     |     |            |     |            |       |            |
| Alecensa  | -      | -     | 0.2   | 0.3   | 0.7    | -          |     |            |     |            |       |            |
| Akynteo   | -      | -     | 0.0   | 0.0   | 0.0    | -          |     |            |     |            |       |            |
| Aloxi   | 0.1    | 0.0   | 0.1   | 0.1   | 0.1    | 0.0        |     |            |     |            |       |            |
| Other products                                  | 0.8    | 0.9   | 0.8   | 0.6   | 0.8    | 0.0        |     |            |     |            |       |            |
| Tamiflu   | 6.7    | 0.0   | 0.0   | 1.5   | 7.0    | +4.5       |     |            |     |            |       |            |
| Ordinary use                                    | 6.7    | 0.0   | 0.0   | 1.5   | 7.0    | +4.5       |     |            |     |            |       |            |
| Govt. stockpiles etc.                           | 0.0    | -     | -     | 0.0   | 0.0    | 0.0        |     |            |     |            |       |            |
| Royalties and other operating income            | 3.7    | 3.9   | 7.0   | 15.9  | 4.3    | +16.2      |     |            |     |            |       |            |
| Revenues  | 117.1  | 123.1 | 127.6 | 131.1 | 119.9  | +2.4       |     |            |     |            |       |            |
| Domestic  | 90.8   | 95.4  | 96.4  | 107.4 | 95.2   | +4.8       |     |            |     |            |       |            |
| Overseas  | 26.2   | 27.7  | 31.2  | 23.7  | 24.7   | (5.7)      |     |            |     |            |       |            |

**Movements of assets and liabilities (Assets, Liabilities, and Net Assets)**

(Billions of yen)

|                                  | Actual  | Actual  |         |         |         |         | Actual            |                   |         |                   |                   |         |                   |                   |         |                   |
|----------------------------------|---------|---------|---------|---------|---------|---------|-------------------|-------------------|---------|-------------------|-------------------|---------|-------------------|-------------------|---------|-------------------|
|                                  | FY2014  | FY2015  |         |         |         |         | FY2016            |                   |         |                   |                   |         |                   |                   |         |                   |
|                                  | Dec. 31 | Mar. 31 | Jun. 30 | Sep. 30 | Dec. 31 | Mar. 31 | vs. Mar. 31, 2015 | vs. Dec. 31, 2015 | Jun. 30 | vs. Jun. 30, 2015 | vs. Dec. 31, 2015 | Sep. 30 | vs. Sep. 30, 2015 | vs. Dec. 31, 2015 | Dec. 31 | vs. Dec. 31, 2015 |
| Trade accounts receivable        | 141.3   | 120.6   | 128.3   | 126.1   | 134.5   | 121.5   | 0.9               | (13.0)            |         |                   |                   |         |                   |                   |         |                   |
| Inventories                      | 139.6   | 147.8   | 145.9   | 154.3   | 161.1   | 167.3   | 19.5              | 6.2               |         |                   |                   |         |                   |                   |         |                   |
| Trade accounts payable           | (35.4)  | (49.2)  | (43.4)  | (46.2)  | (41.2)  | (48.7)  | 0.5               | (7.5)             |         |                   |                   |         |                   |                   |         |                   |
| Other net working capital        | (36.2)  | (30.1)  | (26.2)  | (31.5)  | (39.8)  | (26.3)  | 3.8               | 13.5              |         |                   |                   |         |                   |                   |         |                   |
| Net working capital              | 209.4   | 189.0   | 204.6   | 202.7   | 214.6   | 213.8   | 24.8              | (0.8)             |         |                   |                   |         |                   |                   |         |                   |
| Property, plant and equipment    | 140.2   | 140.7   | 141.9   | 142.8   | 153.5   | 159.4   | 18.7              | 5.9               |         |                   |                   |         |                   |                   |         |                   |
| Intangible assets                | 11.3    | 11.8    | 10.9    | 13.3    | 13.5    | 13.8    | 2.0               | 0.3               |         |                   |                   |         |                   |                   |         |                   |
| Other long-term assets – net     | (3.2)   | (3.1)   | (2.1)   | (2.7)   | (1.3)   | (0.2)   | 2.9               | 1.1               |         |                   |                   |         |                   |                   |         |                   |
| Long-term net operating assets   | 148.4   | 149.4   | 150.7   | 153.4   | 165.8   | 173.0   | 23.6              | 7.2               |         |                   |                   |         |                   |                   |         |                   |
| Net operating assets             | 357.7   | 338.4   | 355.3   | 356.2   | 380.4   | 386.8   | 48.4              | 6.4               |         |                   |                   |         |                   |                   |         |                   |
| Debt                             | (0.2)   | (0.2)   | (0.2)   | (0.8)   | (0.7)   | (0.7)   | (0.5)             | 0.0               |         |                   |                   |         |                   |                   |         |                   |
| Marketable securities            | 116.0   | 114.3   | 120.0   | 121.7   | 134.4   | 112.9   | (1.4)             | (21.5)            |         |                   |                   |         |                   |                   |         |                   |
| Cash and cash equivalents        | 114.0   | 123.6   | 126.6   | 121.6   | 101.7   | 106.8   | (16.8)            | 5.1               |         |                   |                   |         |                   |                   |         |                   |
| Net cash                         | 229.9   | 237.8   | 246.4   | 242.5   | 235.4   | 219.0   | (18.8)            | (16.4)            |         |                   |                   |         |                   |                   |         |                   |
| Other non-operating assets – net | 10.2    | 18.8    | 11.7    | 16.4    | 11.5    | 14.0    | (4.8)             | 2.5               |         |                   |                   |         |                   |                   |         |                   |
| Net non-operating assets         | 240.0   | 256.6   | 258.2   | 258.9   | 246.8   | 233.0   | (23.6)            | (13.8)            |         |                   |                   |         |                   |                   |         |                   |
| Total net assets                 | 597.8   | 594.9   | 613.4   | 615.1   | 627.3   | 619.8   | 24.9              | (7.5)             |         |                   |                   |         |                   |                   |         |                   |
| Total net assets                 |         |         |         |         |         |         |                   |                   |         |                   |                   |         |                   |                   |         |                   |
| Total assets                     | 739.5   | 727.3   | 744.3   | 753.5   | 787.4   | 762.4   | 35.1              | (25.0)            |         |                   |                   |         |                   |                   |         |                   |
| Total liabilities                | (141.8) | (132.3) | (130.9) | (138.4) | (160.1) | (142.7) | (10.4)            | 17.4              |         |                   |                   |         |                   |                   |         |                   |
| Attributable to                  |         |         |         |         |         |         |                   |                   |         |                   |                   |         |                   |                   |         |                   |
| Chugai shareholders              | 596.1   | 593.8   | 612.6   | 613.9   | 625.9   | 618.7   | 24.9              | (7.2)             |         |                   |                   |         |                   |                   |         |                   |
| Non-controlling interests        | 1.7     | 1.2     | 0.9     | 1.1     | 1.4     | 1.1     | (0.1)             | (0.3)             |         |                   |                   |         |                   |                   |         |                   |

Trade accounts receivable: trade receivable and notes receivable

Trade accounts payable: trade payable and notes payable

Other net working capital: accrued receivable (other receivable), accrued payable (other payable), accrued expenses (other current liabilities) etc.

Other long-term assets-net: long-term prepaid expenses, long-term provisions etc.

Other non-operating assets-net: deferred income tax assets, current income tax liabilities etc.

**Movements of assets and liabilities**

The consolidated balance sheet has been prepared in accordance with the IAS No. 1, "Presentation of Financial Statements." On the other hand, "Movements of assets and liabilities" including net operating assets (NOA) are a reconfiguration of the consolidated balance sheet as internal indicators and are identical to the indicators disclosed by Roche. Furthermore, no items from the assets and liabilities of IFRS have been excluded, as the Core results concept only applies to the income statement.

**Movements of free cash flows**

(Billions of yen)

|  | Actual | Actual |        |        |        | Actual |     |     |      |
|--|--------|--------|--------|--------|--------|--------|-----|-----|------|
|  | FY2014 | FY2015 |        |        |        | FY2016 |     |     |      |
|  | 1-12   | 1-3    | 1-6    | 1-9    | 1-12   | 1-3    | 1-6 | 1-9 | 1-12 |
|  | YTD    | YTD    | YTD    | YTD    | YTD    | YTD    | YTD | YTD | YTD  |
| Operating profit – IFRS basis  | 75.9   | 20.7   | 43.2   | 67.1   | 86.8   | 20.1   |     |     |      |
| Depreciation and impairment of property, plant and equipment                       | 15.5   | 3.5    | 7.0    | 10.5   | 14.2   | 3.6    |     |     |      |
| Amortization and impairment of intangible assets                                   | 1.4    | 0.7    | 2.6    | 3.0    | 3.5    | 0.4    |     |     |      |
| Other cash adjustment on operating profit  | 3.7    | 0.2    | (0.7)  | (0.0)  | 1.0    | 1.0    |     |     |      |
| Operating profit, net of operating cash adjustments                                | 96.4   | 25.0   | 52.1   | 80.6   | 105.4  | 25.0   |     |     |      |
| (Increase) decrease in trade accounts receivable                                   | (30.2) | 20.6   | 13.0   | 15.1   | 6.7    | 12.9   |     |     |      |
| (Increase) decrease in inventories   | (12.2) | (8.5)  | (6.7)  | (15.5) | (23.3) | (7.0)  |     |     |      |
| Increase (decrease) in trade accounts payable                                      | (0.6)  | 13.9   | 8.0    | 10.9   | 5.9    | 7.5    |     |     |      |
| Change in other net working capital etc.   | 9.7    | (4.5)  | (7.3)  | (1.1)  | (5.2)  | (7.1)  |     |     |      |
| Total (increase) decrease in net working capital etc.                              | (33.3) | 21.4   | 7.0    | 9.4    | (15.9) | 6.3    |     |     |      |
| Investment in property, plant and equipment  | (16.2) | (5.1)  | (10.9) | (15.5) | (18.4) | (17.1) |     |     |      |
| Investment in intangible assets  | (2.9)  | (2.1)  | (2.9)  | (5.9)  | (6.5)  | (0.8)  |     |     |      |
| Operating free cash flow   | 43.9   | 39.2   | 45.3   | 68.6   | 64.6   | 13.5   |     |     |      |
| as % of revenues   | 9.5%   | 33.5%  | 18.9%  | 18.7%  | 13.0%  | 11.3%  |     |     |      |
| Treasury activities (interest income/expenses, foreign exchange gains/losses etc.) | 0.3    | 1.7    | 2.6    | 3.0    | 1.6    | 1.3    |     |     |      |
| Tax paid   | (25.2) | (15.5) | (16.0) | (28.2) | (29.1) | (12.3) |     |     |      |
| Dividends paid   | (25.5) | (14.6) | (14.8) | (29.3) | (29.4) | (17.8) |     |     |      |
| Free cash flow   | (6.5)  | 10.8   | 17.2   | 14.2   | 7.6    | (15.3) |     |     |      |
| Transaction in own equity instruments  | 1.2    | 0.4    | 0.8    | 1.3    | 1.4    | 0.2    |     |     |      |
| Net effect of currency translation on net cash                                     | 0.7    | (3.2)  | (1.4)  | (2.8)  | (3.5)  | (1.3)  |     |     |      |
| Net change in net cash   | (4.5)  | 7.9    | 16.5   | 12.6   | 5.5    | (16.4) |     |     |      |

Other cash adjustment on operating profit: adjustments for all non-cash income and expense items other than amortization expenses and impairment included in operating profit (such as loss on inventory differences, reserve for doubtful accounts, stock option expenses, loss on asset retirement, and increase/decrease in reserves) as well as all non-operating income and expense cash flows relating to net operating assets (NOA) (including proceeds from the sales of assets and reserve payments)

Operating free cash flow (FCF): pretax cash flow after adjusting changes in working capital and operating investments in assets (tangible and intangible) to "operating profit, net of operating cash adjustments," which shows the company's cash generation ability from operating activities.

Free cash flow: the ability to generate net cash from a management perspective after deducting tax, dividends, and other payments from operating FCF.

Net change in net cash: increases and decreases in marketable securities and interest-bearing debt are included.

**Movements of free cash flows:**

The consolidated statement of cash flows has been prepared in accordance with the IAS No. 7, "Statement of Cash Flows." The FCF is a reconfiguration of the consolidated statement of cash flows as internal indicators and is identical to the indicators disclosed by Roche. Furthermore, no items from the FCF have been excluded, as the Core results concept only applies to the income statement.

The concepts of operating profit, operating FCF and movements of assets and liabilities including NOA presented in the previous page are mutually consistent.

## Performance indicators

|   | Units           | Actual        | Actual        |               |               |               | Actual        |               |               |               | Forecast (Jan 28th announced) |
|---|-----------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|-------------------------------|
|   |                 | FY2014        | FY2015        |               |               |               | FY2016        |               |               |               | FY2016                        |
|   |                 | 1-12          | 1-3           | 1-6           | 1-9           | 1-12          | 1-3           | 1-6           | 1-9           | 1-12          | 1-12                          |
|   |                 | As of Dec. 31 | As of Mar. 31 | As of Jun. 30 | As of Sep. 30 | As of Dec. 31 | As of Mar. 31 | As of Jun. 30 | As of Sep. 30 | As of Dec. 31 | As of Dec. 31                 |
| Ratio of net income to equity attributable to Chugai shareholders (ROE) | %               | 8.7           | 2.5           | 5.0           | 7.9           | 10.0          | 2.3           |               |               |               |                               |
| Ratio of profit before taxes to total assets (ROA)                      | %               | 10.6          | 2.9           | 5.9           | 9.0           | 11.4          | 2.6           |               |               |               |                               |
| Ratio of equity attributable to Chugai shareholders                     | %               | 80.6          | 81.6          | 82.3          | 81.5          | 79.5          | 81.1          |               |               |               |                               |
| Equity per share attributable to Chugai shareholders (BPS)              | Yen             | 1,092.90      | 1,088.25      | 1,122.33      | 1,124.39      | 1,146.17      | 1,132.81      |               |               |               |                               |
| Ratio of dividends to equity attributable to Chugai shareholders (DOE)  | %               | 4.5           | 5.2           |               |               |               |               |               |               |               |                               |
| Core return on net operating assets (Core RONOA)                        | %               | 14.8          | 4.5           | 9.2           | 14.2          | 17.1          | 3.9           |               |               |               |                               |
| Cash conversion cycle (CCC)   | Months          | 9.6           | 8.3           | 8.6           | 8.7           | 9.4           | 9.0           |               |               |               |                               |
| Net cash turnover period  | Months          | 6.0           | 6.1           | 6.2           | 5.9           | 5.7           | 5.5           |               |               |               |                               |
| Number of employees   |                 | 7,023         | 7,009         | 7,196         | 7,177         | 7,169         | 7,137         |               |               |               |                               |
| Investment on property, plant and equipment                             | Billions of yen | 16.3          | 4.0           | 7.8           | 13.5          | 28.7          | 9.7           |               |               |               | 19.0                          |
| Depreciation  | Billions of yen | 13.7          | 3.4           | 6.9           | 10.4          | 14.0          | 3.5           |               |               |               | 14.5                          |
| Investment on intangible assets   | Billions of yen | 3.1           |               |               |               | 5.8           |               |               |               |               |                               |
| Amortization  | Billions of yen | 1.2           |               |               |               | 1.6           |               |               |               |               |                               |

Core RONOA: Core operating profit / Net operating assets

CCC: [Trade accounts receivable/Sales + (Inventories - Trade accounts payable)/Cost of sales]\* passed months

Net cash turnover period: Net cash/Revenue\* passed months

Ratio of net income to equity attributable to Chugai shareholders (ROE), Ratio of profit before taxes to total assets (ROA), and Core return on net operating assets (Core RONOA) are not annualized.

**Development pipeline (as of April 22, 2016)**

| Development code<br>(Compound number)   | Indication<br># Additional indication                   | Stage<br>(Date)                  | Generic name<br>Product name<br>Dosage form   | Origin<br>Overseas name<br>(Collaborator)          | Mode of Action  |
|---|---|----------------------------------|---|--|---|
| <b>Oncology</b>                         |   |                                  |   |  |   |
| RG340<br>(Ro09-1978)                    | Gastric cancer (adjuvant)<br>#                          | Approved<br>(15/11)              | capecitabine<br>Xeloda<br>Oral                | Roche<br>Xeloda<br>(Yakult Honsha)                 | Antimetabolite, 5-FU derivative   |
| AF802 / RG7853<br>(CH5424802/RO5424802) | Non-small cell lung cancer<br>(NSCLC) [post-crizotinib] | Approved<br>(15/12)<br>US        | alectinib<br>Alecensa<br>Oral                 | In-house<br>Alecensa<br>(Roche)                    | ALK inhibitor   |
|   |   | Filed<br>(15/09)<br>Europe       |   |  |   |
| NSCLC [1st line]                        | Phase III<br>Overseas                                   |                                  |   |  |   |
| RG435<br>(RO4876646)                    | Cervical Cancer<br>#                                    | Filed<br>(15/09)                 | bevacizumab<br>Avastin<br>Injection           | Roche<br>Avastin                                   | Anti-VEGF (Vascular Endothelial Growth Factor)<br>humanized monoclonal antibody |
|   | Renal cell carcinoma<br>#                               | Phase III<br>Multinational study |   |  |   |
| RG1273<br>(RO4368451)                   | Breast cancer (adjuvant)<br>#                           | Phase III<br>Multinational study | pertuzumab<br>Perjeta<br>Injection            | Roche<br>Perjeta                                   | HER2 dimerization inhibitory humanized<br>monoclonal antibody                   |
|   | Gastric cancer<br>#                                     | Phase III<br>Multinational study |   |  |   |
| RG3502<br>(RO5304020)                   | Breast cancer (adjuvant)<br>#                           | Phase III<br>Multinational study | trastuzumab emtansine<br>Kadcyla<br>Injection | Roche<br>Kadcyla                                   | Anti-HER2 antibody-tubulin polymerization<br>inhibitor conjugate                |
| GA101 / RG7159<br>(RO5072759)           | Aggressive non-Hodgkin's lymphoma<br>(NHL)              | Phase III<br>Multinational study | obinutuzumab<br>Injection                     | Roche<br>Gazyva/Gazyvaro (EU)<br>(Nippon Shinyaku) | Glycoengineered type II anti-CD20 monoclonal<br>antibody                        |
|   | Indolent NHL  | Phase III<br>Multinational study |   |  |   |

| Development code<br>(Compound number) | Indication<br># Additional indication        | Stage<br>(Date)                  | Generic name<br>Product name<br>Dosage form | Origin<br>Overseas name<br>(Collaborator)               | Mode of Action                                |
|---------------------------------------|--|----------------------------------|---|---|---|
| RG7446<br>(MPDL3280A)                 | NSCLC  | Phase III<br>Multinational study | atezolizumab<br><br>Injection               | Roche<br>Tecentriq                                      | Engineered anti-PDL1 monoclonal antibody      |
|                                       | NSCLC (adjuvant)                             | Phase III<br>Multinational study |   |   |   |
|                                       | Bladder cancer                               | Phase III<br>Multinational study |   |   |   |
|                                       | Muscle Invasive bladder Cancer<br>(adjuvant) | Phase III<br>Multinational study |   |   |   |
|                                       | Renal cell carcinoma                         | Phase III<br>Multinational study |   |   |   |
| GC33 / RG7686<br>(GC33/RO5137382)     | Hepatocellular carcinoma                     | Phase II<br>Multinational study  | codrituzumab<br><br>Injection               | In-house<br><br>(Roche)                                 | Anti-Glypican-3 humanized monoclonal antibody |
| CKI27 / RG7304<br>(RO5126766)         | Solid tumors                                 | Phase I                          | Oral  | In-house<br><br>(Roche)                                 | Raf and MEK dual inhibitor                    |
|                                       |  | Phase I<br>Overseas              |   |   |   |
| RG7596<br>(RO5541077)                 | NHL  | Phase I                          | polatuzumab vedotin<br><br>Injection        | Roche   | Anti-CD79b antibody-drug conjugate            |
| RG7604<br>(GDC-0032)                  | Solid tumors                                 | Phase I                          | taselisib<br><br>Oral                       | Roche   | PI3K inhibitor                                |
| RG7440<br>(GDC-0068)                  | Solid tumors                                 | Phase I                          | ipatasertib<br><br>Oral                     | Roche/Array BioPharma                                   | AKT inhibitor                                 |
| <b><u>Bone and Joint Diseases</u></b> |  |                                  |   |   |   |
| RG484<br>(Ro200-5450po)               | Osteoporosis                                 | Launched<br>(16/04)              | ibandronic acid<br>Bonviva<br>Oral          | Roche<br>Bonviva/Boniva (US)<br>(Taisho Pharmaceutical) | Bisphosphonate                                |
| ED-71<br>(ED-71)                      | Osteoporosis                                 | Phase III<br>China               | eldecalcitol<br>Edirol<br>Oral              | In-house  | Activated vitamin D <sub>3</sub> agent        |

| Development code<br>(Compound number) | Indication<br># Additional indication                                 | Stage<br>(Date)                   | Generic name<br>Product name<br>Dosage form | Origin<br>Overseas name<br>(Collaborator)     | Mode of Action   |
|---------------------------------------|---|-----------------------------------|---|---|--|
| <b>Renal Diseases</b>                 |   |                                   |   |   |  |
| EOS789<br>(EOS789)                    | Hyperphosphatemia   | Phase I                           | Oral  | In-house                                      | -  |
| <b>Autoimmune Diseases</b>            |   |                                   |   |   |  |
| MRA / RG1569<br>(RO4877533)           | Large-vessel vasculitis<br>#  | Phase III                         | tocilizumab<br>Actemra                      | In-house<br>Actemra/RoActemra (EU)<br>(Roche) | Humanized anti-human IL-6 receptor monoclonal antibody |
|                                       | Giant cell arteritis<br>#   | Phase III<br>Overseas             | Injection                                   |   |  |
|                                       | Systemic sclerosis<br>#   | Phase III<br>Multinational study  |   |   |  |
| SA237<br>(SA237)                      | Neuromyelitis optica (NMO)  | Phase III<br>Multinational study* | Injection                                   | In-house                                      | Anti-IL-6 receptor humanized monoclonal antibody       |
| <b>Central Nervous System</b>         |   |                                   |   |   |  |
| RG1450<br>(RO4909832)                 | Alzheimer's disease   | Phase III<br>Multinational study  | gantenerumab<br>Injection                   | Roche/MorphoSys                               | Anti-amyloid-beta human monoclonal antibody            |
| RG1662<br>(RO5186582)                 | Improvement of intellectual ability in individuals with Down syndrome | Phase I                           | basmisanil<br>Oral                          | Roche   | GABAA $\alpha$ 5 receptor antagonist                   |
| <b>Respiratory Diseases</b>           |   |                                   |   |   |  |
| RG3637<br>(RO5490255)                 | Asthma  | Phase III<br>Multinational study  | lebrikizumab                                | Roche   | Anti-IL-13 humanized monoclonal antibody               |
|                                       | Idiopathic pulmonary fibrosis   | Phase II<br>Multinational study   | Injection                                   |   |  |
| <b>Others</b>                         |   |                                   |   |   |  |
| ACE910 / RG6013<br>(RO5534262)        | Hemophilia A  | Phase III<br>Multinational study  | emicizumab<br>Injection                     | In-house<br>(Roche)                           | Anti-FIXa/FX bispecific antibody                       |
| CIM331<br>(CIM331)                    | Atopic dermatitis   | Phase II<br>Multinational study*  | nemolizumab                                 | In-house                                      | Anti-IL-31 receptor humanized monoclonal antibody      |
|                                       | Pruritus in dialysis patients   | Phase II                          | Injection                                   |   |  |

| Development code<br>(Compound number) | Indication<br># Additional indication | Stage<br>(Date)      | Generic name<br>Product name<br>Dosage form | Origin<br>Overseas name<br>(Collaborator)         | Mode of Action        |
|---------------------------------------|---------------------------------------|----------------------|---|---|-----------------------|
| URC102<br>(URC102)                    | Gout                                  | Phase II<br>Overseas | Oral  | In-house/JW Pharmaceutical<br>(JW Pharmaceutical) | URAT1 inhibitor       |
| PCO371<br>(PCO371)                    | Hypoparathyroidism                    | Phase I<br>Overseas  | Oral  | In-house  | PTH1 receptor agonist |

In principle, completion of first dose is regarded as the start of clinical studies in each phase.

\* Multinational study managed by Chugai

## Changes from the last announcement on January 28, 2016

### Bone and Joint Diseases

-RG484 Approved → Launched (Osteoporosis)

## R&D Activities (Jan. 1, 2016- Apr. 22, 2016)

As for clinical development activities, Chugai saw progress as described below:

### Oncology

- We decided to discontinue development of the anti-HER2 antibody-tubulin polymerization inhibitor conjugate RG3502 for gastric cancer in consideration of the fact that the primary endpoint was not achieved in the Phase III multinational study (the GATSBY study).

### Bone and Joint Diseases

- We obtained approval for the indication of osteoporosis for bisphosphonate RG484 (oral) in January, and launched in April, 2016.



## Major clinical trials in oncology field currently running in Japan

| Theme                                     | Expected Indication                          | Regimen   | Stage   | Planned filing year |
|---|--|---|---|---------------------|
| RG1273 (pertuzumab)<br>Perjeta            | Breast cancer (adjuvant)                     | Herceptin + chemotherapy ± RG1273   | APHINITY study<br>Phase III multinational study     | 2017                |
|   | Gastric cancer                               | Herceptin + chemotherapy ± RG1273   | JACOB study<br>Phase III multinational study        | 2018                |
| RG3502 (trastuzumab emtansine)<br>Kadcyla | Breast cancer (adjuvant)                     | Kadcyla + Perjeta vs.<br>Herceptin + Perjeta + chemotherapy                   | KAITLIN study<br>Phase III multinational study      | 2019 and beyond     |
| GA101/ RG7159<br>(obinutuzumab)           | Aggressive NHL                               | GA101 + CHOP vs. Rituxan + CHOP<br>(G-CHOP vs. R-CHOP)                        | GOYA study<br>Phase III multinational study         | 2017                |
|   | Indolent NHL                                 | GA101 + chemotherapy vs. Rituxan + chemotherapy<br>(G-chemo vs. R-chemo)      | GALLIUM study<br>Phase III multinational study      | 2017                |
| RG7446<br>(atezolizumab)                  | NSCLC  | RG7446 vs. docetaxel  | OAK study<br>Phase III multinational study          | 2017                |
|   |  | RG7446  | BIRCH study<br>Phase II multinational study         |                     |
|   |  | Non-squamous, PD-L1 positive<br>RG7446 vs. chemotherapy                       | IMpower 110 study<br>Phase III multinational study  |                     |
|   |  | Non-squamous<br>RG7446 + chemotherapy ± Avastin vs.<br>Chemotherapy + Avastin | IMpower 150 study<br>Phase III multinational study  |                     |
|   |  | Non-Squamous<br>Chemotherapy ± RG7446   | IMpower 132 study<br>Phase III multinational study  |                     |
|   |  | Squamous<br>Chemotherapy ± RG7446   | IMpower 131 study<br>Phase III multinational study  |                     |
|   | NSCLC (adjuvant)                             | RG7446 vs. best supportive care   | IMpower 010 study<br>Phase III multinational study  | 2019 and beyond     |
|   | Bladder cancer                               | RG7446 vs. chemotherapy   | IMvigor 211 study<br>Phase III multinational study  | 2017                |
|   | Muscle invasive bladder cancer<br>(adjuvant) | RG7446 vs. observation  | IMvigor 010 study<br>Phase III multinational study  | 2019 and beyond     |
|   | Renal cell carcinoma                         | RG7446 + Avastin vs. sunitinib  | IMmotion 151 study<br>Phase III multinational study | 2018                |
| RG435 (bevacizumab)<br>Avastin            | Cervical cancer                              | Avastin + chemotherapy  | Filed   | -                   |